Metabolomic Diagnostics

Metabolomic Diagnostics is a Cork, Ireland-based deep-tech diagnostics company founded in 2013, specializing in biomarker discovery and assay development for complex diseases, particularly in maternal health. Its proprietary platform integrates mass spectrometry multiplexing with advanced bioinformatics to develop diagnostic tests, with its lead program targeting the early screening of preterm preeclampsia. In September 2024, the company entered into an agreement to be acquired by Trinity Biotech, aiming to accelerate the commercialization of its maternal health solutions and expand its market presence.

Integrated pipeline combining Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) for biomarker multiplexing with proprietary informatics and statistical solutions for biomarker discovery and clinical assay development.

The prenatal and maternal health diagnostics market is competitive, featuring large diagnostic companies and specialized players. Metabolomic Diagnostics aims to differentiate through its deep-tech, mass spectrometry-based platform offering high-specificity biomarker panels for personalized risk assessment, a approach distinct from more common genomic or simpler biochemical tests.